BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 11, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CXA-101: Phase II data

Data from the mMITT population (n=103) of a double-blind, active-controlled, international Phase II trial showed that IV CXA-101 every 8 hours for 7-10 days led to a microbiologic cure rate of 83% at the TOC visit 6-9 days after the end of therapy vs. 76% for IV ceftazidime every 8 hours. In the ME population (n=82), CXA-101 led to a microbiologic cure rate of 86% at the TOC visit vs. 93%...

Read the full 333 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >